ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer

Breast cancer (BC) development and progression is complex and still not fully understood. The expression or dysregulation of a variety of transcription factors has been suggested as contributing to disease severity and a poor prognosis. Therefore, the present study was designed to systematically out...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical breast cancer 2021-08, Vol.21 (4), p.e319-e331
Hauptverfasser: Shatnawi, Aymen, Ayoub, Nehad M., Alkhalifa, Amer E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e331
container_issue 4
container_start_page e319
container_title Clinical breast cancer
container_volume 21
creator Shatnawi, Aymen
Ayoub, Nehad M.
Alkhalifa, Amer E.
description Breast cancer (BC) development and progression is complex and still not fully understood. The expression or dysregulation of a variety of transcription factors has been suggested as contributing to disease severity and a poor prognosis. Therefore, the present study was designed to systematically outline ING4 expression and characteristics in clinical samples and cell lines of BC. A METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset was obtained from a cBioPortal public domain. ING4 gene expression, putative copy number alterations, and pertinent tumor information were retrieved. ING4 gene expression was identified for 1904 BC patients. ING4 mRNA expression data in BC cell lines were obtained from the Cancer Cell Line Encyclopedia. Analyses were conducted for associations between ING4 expression and age at diagnosis, tumor clinicopathologic characteristics, and molecular subtypes. The prognostic value of ING4 in BC patients was evaluated using Kaplan-Meier survival analysis. The ING4 mRNA expression log intensity mean was 6.95, and 1005 (52.8%) of patients were determined to have high ING4 mRNA expression (mRNA log intensity > 6.95). Although ING4 gene expression correlated significantly and negatively with the Nottingham Prognostic Index and the number of positive lymph nodes (P < .05) and positively with overall survival time (P < .001). However, these correlations were weak in magnitude (r ∼ 0.1). The expression of ING4 was significantly associated with tumor grade, hormone receptor expression, human epidermal growth factor receptor 2, and molecular subtype. ING4 copy number alteration was also significantly associated with several clinicopathologic and prognostic factors. Kaplan-Meier survival analysis demonstrated greater overall survival for BC patients with high ING4 expression (P = .0046). Stratification of the data by menopausal status and tumor characteristics revealed a significant effect of ING4 expression on survival among premenopausal patients and women with a nonluminal subtype. Furthermore, the expression of ING4 in BC cell lines was significantly greater in luminal A and basal-like cells compared with human epidermal growth factor receptor 2-positive cells, which was also observed in the clinical samples. The present study showed that ING4 gene expression is modulated in BC. High ING4 gene expression was associated with favorable prognostic parameters and positive clinical outcomes in our series of BC patients.
doi_str_mv 10.1016/j.clbc.2020.11.011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2471458781</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1526820920302950</els_id><sourcerecordid>2471458781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-ab7cf3ea276e87fdb167d8d9c0cf28e40249c9061650f3cbca40b453481d419a3</originalsourceid><addsrcrecordid>eNp9kE-P1DAMxSMEYv_AF-CAcuTSIU7TNJW4LNWyu9IILiCOUeq6TEadpiSZFXx7MpqFI77Yst97kn-MvQGxAQH6_X6D84AbKWRZwEYAPGOX0NWmElrr52VupK6MFN0Fu0ppL4TUNYiX7KIupXRnLpl7-Hyn-O2vNVJKPix865YxoVuJl4HfpBTQu3y6fPd5x_vZLx7D6vIuzOGHR97vXHSYKfqUPSbuF_4xkkuZ925Biq_Yi8nNiV4_9Wv27dPt1_6-2n65e-hvthXWjc6VG1qcanKy1WTaaRxAt6MZOxQ4SUNKSNVhJzToRkw1DuiUGFRTKwOjgs7V1-zdOXeN4eeRUrYHn5Dm2S0UjslK1YJqTGugSOVZijGkFGmya_QHF39bEPaE1u7tCa09obUAtqAtprdP-cfhQOM_y1-WRfDhLKDy5aOnaBN6KghGHwmzHYP_X_4fgteKhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471458781</pqid></control><display><type>article</type><title>ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Shatnawi, Aymen ; Ayoub, Nehad M. ; Alkhalifa, Amer E.</creator><creatorcontrib>Shatnawi, Aymen ; Ayoub, Nehad M. ; Alkhalifa, Amer E.</creatorcontrib><description>Breast cancer (BC) development and progression is complex and still not fully understood. The expression or dysregulation of a variety of transcription factors has been suggested as contributing to disease severity and a poor prognosis. Therefore, the present study was designed to systematically outline ING4 expression and characteristics in clinical samples and cell lines of BC. A METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset was obtained from a cBioPortal public domain. ING4 gene expression, putative copy number alterations, and pertinent tumor information were retrieved. ING4 gene expression was identified for 1904 BC patients. ING4 mRNA expression data in BC cell lines were obtained from the Cancer Cell Line Encyclopedia. Analyses were conducted for associations between ING4 expression and age at diagnosis, tumor clinicopathologic characteristics, and molecular subtypes. The prognostic value of ING4 in BC patients was evaluated using Kaplan-Meier survival analysis. The ING4 mRNA expression log intensity mean was 6.95, and 1005 (52.8%) of patients were determined to have high ING4 mRNA expression (mRNA log intensity &gt; 6.95). Although ING4 gene expression correlated significantly and negatively with the Nottingham Prognostic Index and the number of positive lymph nodes (P &lt; .05) and positively with overall survival time (P &lt; .001). However, these correlations were weak in magnitude (r ∼ 0.1). The expression of ING4 was significantly associated with tumor grade, hormone receptor expression, human epidermal growth factor receptor 2, and molecular subtype. ING4 copy number alteration was also significantly associated with several clinicopathologic and prognostic factors. Kaplan-Meier survival analysis demonstrated greater overall survival for BC patients with high ING4 expression (P = .0046). Stratification of the data by menopausal status and tumor characteristics revealed a significant effect of ING4 expression on survival among premenopausal patients and women with a nonluminal subtype. Furthermore, the expression of ING4 in BC cell lines was significantly greater in luminal A and basal-like cells compared with human epidermal growth factor receptor 2-positive cells, which was also observed in the clinical samples. The present study showed that ING4 gene expression is modulated in BC. High ING4 gene expression was associated with favorable prognostic parameters and positive clinical outcomes in our series of BC patients. ING4 could be used as a potential therapeutic target in BC-targeted therapy. We found that ING4 is an essential player in breast cancer pathogenesis. High ING4 gene expression was associated with favorable prognostics parameters and positive clinical outcomes in the investigated patient dataset. ING4 can be used as an indicator of treatment success and can be used as a therapeutic target in breast cancer-targeted therapy.</description><identifier>ISSN: 1526-8209</identifier><identifier>EISSN: 1938-0666</identifier><identifier>DOI: 10.1016/j.clbc.2020.11.011</identifier><identifier>PMID: 33334698</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Carcinoma - genetics ; Carcinoma - mortality ; Carcinoma - pathology ; cBioPortal ; CCLE ; Cell Cycle Proteins - genetics ; Cell Cycle Proteins - metabolism ; Cell Line, Tumor ; Female ; Gene expression ; Homeodomain Proteins - genetics ; Homeodomain Proteins - metabolism ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; RNA, Messenger - metabolism ; Survival ; Survival Rate ; Tumor Suppressor Proteins - genetics ; Tumor Suppressor Proteins - metabolism ; Young Adult</subject><ispartof>Clinical breast cancer, 2021-08, Vol.21 (4), p.e319-e331</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-ab7cf3ea276e87fdb167d8d9c0cf28e40249c9061650f3cbca40b453481d419a3</citedby><cites>FETCH-LOGICAL-c356t-ab7cf3ea276e87fdb167d8d9c0cf28e40249c9061650f3cbca40b453481d419a3</cites><orcidid>0000-0003-2284-4370 ; 0000-0001-6435-3727</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clbc.2020.11.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33334698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shatnawi, Aymen</creatorcontrib><creatorcontrib>Ayoub, Nehad M.</creatorcontrib><creatorcontrib>Alkhalifa, Amer E.</creatorcontrib><title>ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer</title><title>Clinical breast cancer</title><addtitle>Clin Breast Cancer</addtitle><description>Breast cancer (BC) development and progression is complex and still not fully understood. The expression or dysregulation of a variety of transcription factors has been suggested as contributing to disease severity and a poor prognosis. Therefore, the present study was designed to systematically outline ING4 expression and characteristics in clinical samples and cell lines of BC. A METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset was obtained from a cBioPortal public domain. ING4 gene expression, putative copy number alterations, and pertinent tumor information were retrieved. ING4 gene expression was identified for 1904 BC patients. ING4 mRNA expression data in BC cell lines were obtained from the Cancer Cell Line Encyclopedia. Analyses were conducted for associations between ING4 expression and age at diagnosis, tumor clinicopathologic characteristics, and molecular subtypes. The prognostic value of ING4 in BC patients was evaluated using Kaplan-Meier survival analysis. The ING4 mRNA expression log intensity mean was 6.95, and 1005 (52.8%) of patients were determined to have high ING4 mRNA expression (mRNA log intensity &gt; 6.95). Although ING4 gene expression correlated significantly and negatively with the Nottingham Prognostic Index and the number of positive lymph nodes (P &lt; .05) and positively with overall survival time (P &lt; .001). However, these correlations were weak in magnitude (r ∼ 0.1). The expression of ING4 was significantly associated with tumor grade, hormone receptor expression, human epidermal growth factor receptor 2, and molecular subtype. ING4 copy number alteration was also significantly associated with several clinicopathologic and prognostic factors. Kaplan-Meier survival analysis demonstrated greater overall survival for BC patients with high ING4 expression (P = .0046). Stratification of the data by menopausal status and tumor characteristics revealed a significant effect of ING4 expression on survival among premenopausal patients and women with a nonluminal subtype. Furthermore, the expression of ING4 in BC cell lines was significantly greater in luminal A and basal-like cells compared with human epidermal growth factor receptor 2-positive cells, which was also observed in the clinical samples. The present study showed that ING4 gene expression is modulated in BC. High ING4 gene expression was associated with favorable prognostic parameters and positive clinical outcomes in our series of BC patients. ING4 could be used as a potential therapeutic target in BC-targeted therapy. We found that ING4 is an essential player in breast cancer pathogenesis. High ING4 gene expression was associated with favorable prognostics parameters and positive clinical outcomes in the investigated patient dataset. ING4 can be used as an indicator of treatment success and can be used as a therapeutic target in breast cancer-targeted therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>cBioPortal</subject><subject>CCLE</subject><subject>Cell Cycle Proteins - genetics</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Female</subject><subject>Gene expression</subject><subject>Homeodomain Proteins - genetics</subject><subject>Homeodomain Proteins - metabolism</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Middle Aged</subject><subject>RNA, Messenger - metabolism</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumor Suppressor Proteins - metabolism</subject><subject>Young Adult</subject><issn>1526-8209</issn><issn>1938-0666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE-P1DAMxSMEYv_AF-CAcuTSIU7TNJW4LNWyu9IILiCOUeq6TEadpiSZFXx7MpqFI77Yst97kn-MvQGxAQH6_X6D84AbKWRZwEYAPGOX0NWmElrr52VupK6MFN0Fu0ppL4TUNYiX7KIupXRnLpl7-Hyn-O2vNVJKPix865YxoVuJl4HfpBTQu3y6fPd5x_vZLx7D6vIuzOGHR97vXHSYKfqUPSbuF_4xkkuZ925Biq_Yi8nNiV4_9Wv27dPt1_6-2n65e-hvthXWjc6VG1qcanKy1WTaaRxAt6MZOxQ4SUNKSNVhJzToRkw1DuiUGFRTKwOjgs7V1-zdOXeN4eeRUrYHn5Dm2S0UjslK1YJqTGugSOVZijGkFGmya_QHF39bEPaE1u7tCa09obUAtqAtprdP-cfhQOM_y1-WRfDhLKDy5aOnaBN6KghGHwmzHYP_X_4fgteKhA</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Shatnawi, Aymen</creator><creator>Ayoub, Nehad M.</creator><creator>Alkhalifa, Amer E.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2284-4370</orcidid><orcidid>https://orcid.org/0000-0001-6435-3727</orcidid></search><sort><creationdate>202108</creationdate><title>ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer</title><author>Shatnawi, Aymen ; Ayoub, Nehad M. ; Alkhalifa, Amer E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-ab7cf3ea276e87fdb167d8d9c0cf28e40249c9061650f3cbca40b453481d419a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>cBioPortal</topic><topic>CCLE</topic><topic>Cell Cycle Proteins - genetics</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Female</topic><topic>Gene expression</topic><topic>Homeodomain Proteins - genetics</topic><topic>Homeodomain Proteins - metabolism</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Middle Aged</topic><topic>RNA, Messenger - metabolism</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumor Suppressor Proteins - metabolism</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shatnawi, Aymen</creatorcontrib><creatorcontrib>Ayoub, Nehad M.</creatorcontrib><creatorcontrib>Alkhalifa, Amer E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical breast cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shatnawi, Aymen</au><au>Ayoub, Nehad M.</au><au>Alkhalifa, Amer E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer</atitle><jtitle>Clinical breast cancer</jtitle><addtitle>Clin Breast Cancer</addtitle><date>2021-08</date><risdate>2021</risdate><volume>21</volume><issue>4</issue><spage>e319</spage><epage>e331</epage><pages>e319-e331</pages><issn>1526-8209</issn><eissn>1938-0666</eissn><abstract>Breast cancer (BC) development and progression is complex and still not fully understood. The expression or dysregulation of a variety of transcription factors has been suggested as contributing to disease severity and a poor prognosis. Therefore, the present study was designed to systematically outline ING4 expression and characteristics in clinical samples and cell lines of BC. A METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) dataset was obtained from a cBioPortal public domain. ING4 gene expression, putative copy number alterations, and pertinent tumor information were retrieved. ING4 gene expression was identified for 1904 BC patients. ING4 mRNA expression data in BC cell lines were obtained from the Cancer Cell Line Encyclopedia. Analyses were conducted for associations between ING4 expression and age at diagnosis, tumor clinicopathologic characteristics, and molecular subtypes. The prognostic value of ING4 in BC patients was evaluated using Kaplan-Meier survival analysis. The ING4 mRNA expression log intensity mean was 6.95, and 1005 (52.8%) of patients were determined to have high ING4 mRNA expression (mRNA log intensity &gt; 6.95). Although ING4 gene expression correlated significantly and negatively with the Nottingham Prognostic Index and the number of positive lymph nodes (P &lt; .05) and positively with overall survival time (P &lt; .001). However, these correlations were weak in magnitude (r ∼ 0.1). The expression of ING4 was significantly associated with tumor grade, hormone receptor expression, human epidermal growth factor receptor 2, and molecular subtype. ING4 copy number alteration was also significantly associated with several clinicopathologic and prognostic factors. Kaplan-Meier survival analysis demonstrated greater overall survival for BC patients with high ING4 expression (P = .0046). Stratification of the data by menopausal status and tumor characteristics revealed a significant effect of ING4 expression on survival among premenopausal patients and women with a nonluminal subtype. Furthermore, the expression of ING4 in BC cell lines was significantly greater in luminal A and basal-like cells compared with human epidermal growth factor receptor 2-positive cells, which was also observed in the clinical samples. The present study showed that ING4 gene expression is modulated in BC. High ING4 gene expression was associated with favorable prognostic parameters and positive clinical outcomes in our series of BC patients. ING4 could be used as a potential therapeutic target in BC-targeted therapy. We found that ING4 is an essential player in breast cancer pathogenesis. High ING4 gene expression was associated with favorable prognostics parameters and positive clinical outcomes in the investigated patient dataset. ING4 can be used as an indicator of treatment success and can be used as a therapeutic target in breast cancer-targeted therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33334698</pmid><doi>10.1016/j.clbc.2020.11.011</doi><orcidid>https://orcid.org/0000-0003-2284-4370</orcidid><orcidid>https://orcid.org/0000-0001-6435-3727</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1526-8209
ispartof Clinical breast cancer, 2021-08, Vol.21 (4), p.e319-e331
issn 1526-8209
1938-0666
language eng
recordid cdi_proquest_miscellaneous_2471458781
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Adult
Aged
Aged, 80 and over
Breast Neoplasms - genetics
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Carcinoma - genetics
Carcinoma - mortality
Carcinoma - pathology
cBioPortal
CCLE
Cell Cycle Proteins - genetics
Cell Cycle Proteins - metabolism
Cell Line, Tumor
Female
Gene expression
Homeodomain Proteins - genetics
Homeodomain Proteins - metabolism
Humans
Kaplan-Meier Estimate
Middle Aged
RNA, Messenger - metabolism
Survival
Survival Rate
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Young Adult
title ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A02%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ING4%20Expression%20Landscape%20and%20Association%20With%20Clinicopathologic%20Characteristics%20in%20Breast%20Cancer&rft.jtitle=Clinical%20breast%20cancer&rft.au=Shatnawi,%20Aymen&rft.date=2021-08&rft.volume=21&rft.issue=4&rft.spage=e319&rft.epage=e331&rft.pages=e319-e331&rft.issn=1526-8209&rft.eissn=1938-0666&rft_id=info:doi/10.1016/j.clbc.2020.11.011&rft_dat=%3Cproquest_cross%3E2471458781%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471458781&rft_id=info:pmid/33334698&rft_els_id=S1526820920302950&rfr_iscdi=true